A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin
Obesity, Overweight
About this trial
This is an interventional treatment trial for Obesity
Eligibility Criteria
Inclusion Criteria: Male or female Aged 18-55 years (both inclusive) at the time of signing informed consent. Body Mass Index (BMI) between 27.0 and 39.9 kg/m^2 (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator. Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator. Exclusion Criteria: Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol HbA1c equal to or greater than 6.5 % (48 mmol/mol) at screening Any laboratory safety parameters at screening outside the below laboratory ranges, see designated reference range documents for specific values: Vitamin D (25-hydroxycholecalciferol) below 12 ng/mL (30 nM) at screening Parathyroid hormone (PTH) outside normal range at screening Total calcium outside normal range at screening Amylase equal to or greater than 2 times upper limit of normal at screening Lipase equal to or greater than 2 times upper limit of normal at screening Calcitonin equal to or greater than 50 ng/L at screening
Sites / Locations
- Novo Nordisk Investigational SiteRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
NNC0487-0111
Placebo
Participants will be randomized to receive NNC0487-0111. The study will be conducted in 3 parts. Part A: Single ascending dose (SAD) Part B and C: Multiple ascending dose (MAD)
Participants will be randomized to receive Placebo. The study will be conducted in 3 parts. Part A: Single ascending dose (SAD). Part B and C: Multiple ascending dose (MAD).